Jesse Duplechain
Otolaryngology · Lafayette, LANPI 1477522068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,960 of the $29,112 with a category attached, or 89.2%. 10 manufacturers reported payments, led by Lumenis BE Inc at 60.0% of the total. Reporting peaked in 2024 at $14,658 and has fallen 81.4% since, to $2,731 in 2025. Among otolaryngology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $222.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$17K
- AbbVie$10K
- Revance Therapeutics, Inc.$1K
- Merz North America, Inc.$444
- Galderma Laboratories, L.p.$79
- Pacira Pharmaceuticals Incorporated$25
- plus $59 from 4 others
What the payments were for
- Speaking & faculty fees$25,96089%
- Food & beverage$3,15111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 3 | $17,460 |
| AbbVie(2 entities) | 99 | $9,818 |
| Revance Therapeutics, Inc. | 14 | $1,227 |
| Merz North America, Inc. | 6 | $444 |
| Galderma Laboratories, L.p. | 4 | $79 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $21 |
| Acacia Pharma Inc | 1 | $21 |
| KCI USA, Inc. | 1 | $13 |
| Apyx Medical Corporation | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$15,460
- M22$2,000
- DAXXIFY$544
- BOTOX COSMETIC$500
How this compares
$29,112 in reported general payments places this provider in the 95th percentile of 218 otolaryngology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 32 | $351 |
| Dexamethasone | 35 | $319 |
| ValacyclovirValacyclovir Hcl | 31 | $293 |
| Gabapentin | 16 | $227 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 29 | $168 |
| Cephalexin | 47 | $156 |
| Dutasteride | 14 | $121 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Lafayette
- James WhiteLafayette$11K
- David ForemanLafayette$5K
- Jason DurelLafayette$4K
- Ryan ChastantLafayette$4K
- Maria DoucetLafayette$3K
- Donald GonzalesNew Orleans$351K
- Kevin McLaughlinCovington$186K
- Adil FatakiaMarrero$148K
- Edward McCoulNew Orleans$92K
- Michael YimShreveport$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.